$PRTG News
Last published 1y ago
- 1y agoGRYPPRTGAlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemGlobeNewswireDOVER, DE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User EcosystemBrittany Kaiser, pioneer in data protection, digital assets, and the
- 1y agoPRTGPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025GlobeNewswireDOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a
- 1y agoPRTGPortage Biotech Regains Full Compliance with Nasdaq Continued Listing RequirementsGlobeNewswireDOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ("Portage"),
- 1y agoPRTGPortage Biotech and Compedica Stock-for-Stock ExchangeGlobeNewswireDOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ("Portage") announce that on June 5, 2025
- 1y agoPRTGPortage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7GlobeNewswireDOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine
- 1y agoPRTGPortage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7GlobeNewswireDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7
- 1y agoPRTGPortage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 TrialGlobeNewswireDOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the
- 1y agoPRTGPortage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsGlobeNewswireDOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced
- 1y agoPRTGPortage Biotech Announces Completion of $2.15 Million Private FinancingGlobeNewswireDOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced
- 1y agoPRTGPortage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New CompanyGlobeNewswireWESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced
- 1y agoPRTGPortage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, LtdGlobeNewswireWESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use
- 1y agoPRTGPortage Biotech Announces Receipt of Nasdaq Noncompliance LetterGlobeNewswireNo impact at this time on the listing of the Company's Ordinary Shares on NasdaqCompany intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage"
- 1y agoPRTGPortage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024GlobeNewswireWESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as
- 2y agoPRTGPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business UpdateGlobeNewswireWESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as
- 2y agoPRTGPortage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business UpdateGlobeNewswireExploration and evaluation of strategic alternatives continuePausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors)Discontinuing the iNKT clinical trial for PORT-2 WESTPORT,
- 2y agoPRTGPortage Biotech Announces 1-for-20 Reverse Stock SplitGlobeNewswireWESTPORT, Conn., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as
- 2y agoPRTGPortage Biotech Announces Plans to Expand its Evaluation of Strategic AlternativesGlobeNewswireWESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
- 2y agoINTSPRTGPortage Biotech Completes Monetization of Intensity Therapeutics (INTS) sharesGlobeNewswireWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
- 2y agoPRTGPortage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business UpdateGlobeNewswireWESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as
- 2y agoPRTGPortage Biotech Reports Business and Strategic UpdateGlobeNewswirePrioritize the adenosine clinical candidates iNKT clinical development paused to focus resourcesCompany will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech
- 2y agoPRTGPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business UpdateGlobeNewswireWESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
- 3y agoPRTGPortage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewswireUpdated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanomaStrong academic interest in the design of
- 3y agoPRTGPortage Biotech Announces $6.0 Million Registered Direct OfferingGlobeNewswireWESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare ConferenceGlobeNewswireWESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid TumorsGlobeNewswireWESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
- 3y agoPRTGPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business UpdateGlobeNewswireWESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
- 3y agoINTSPRTGPortage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business UpdateGlobeNewswireCompany poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led programUpdated interim data for
- 3y agoPRTGPortage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid TumorsGlobeNewswireWESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual MeetingGlobeNewswireInterim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesionsBased on the favorable safety and tolerability data at all doses tested to date, the Company
- 3y agoPRTGPortage Biotech to Participate in Panel Discussion During the 2023 BIO International ConferenceGlobeNewswireWESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireWESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech to Present at Oppenheimer's 33rd Annual Healthcare ConferenceGlobeNewswireWESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022GlobeNewswire- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key
- 3y agoPRTGPortage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in CancerGlobeNewswireTargeting Adenosine for Cancer:Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9th @ 10:30 am ET WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc.
- 3y agoPRTGPortage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership SummitGlobeNewswireWESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination,
- 3y agoPRTGPortage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022GlobeNewswire--Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting-- --Clinical Collaboration Agreement Entered into with Merck for Evaluation of PORT-2
- 4y agoPRTGPortage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewswireWESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the
- 4y agoPRTGPortage Biotech Announces Clinical Trial Collaboration Agreement with MerckGlobeNewswireWESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase
- 4y agoPRTGPortage Biotech Provides Research and Development UpdateGlobeNewswire--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years-- WESTPORT, Conn., Sept.
- 4y agoPRTGPortage Biotech to Present at Upcoming Investor ConferencesGlobeNewswireWESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company's management team wil
- 4y agoPRTGPortage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022GlobeNewswire--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-
- 4y agoPRTGPortage Biotech Announces Leadership UpdatesGlobeNewswireCEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild, MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Portage Biot
- 4y agoPRTGPortage Biotech Announces Results for Fiscal Year Ended March 31, 2022GlobeNewswire--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Pote
- 4y agoPRTGPortage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist PlatformGlobeNewswireWESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance,
- 4y agoPRTGPortage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine PathwayGlobeNewswireAcquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Bo
- 4y agoPRTGPortage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 StudyGlobeNewswireWESTPORT, Conn., June 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance,
- 4y agoPRTGPortage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and StimunityGlobeNewswireCollaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer vacc
- 4y agoPRTGPortage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual MeetingGlobeNewswireWESTPORT, Conn., April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcomin
- 4y agoPRTGPortage Biotech Provides Update on Clinical-Stage and Development ProgramsGlobeNewswirePreliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work toward multiple clinical readouts in 2022 Portage is accelerating studies by expanding regions
- 4y agoPRTGPortage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual MeetingGlobeNewswireWESTPORT, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming